SUNPHARMA - Sun Pharmaceutical Industries Ltd. Share Price

Management's outlook for FY27 indicates an expectation of high single-digit consolidated top-line growth. The company's R&D spending for the forthcoming year is projected to be 6% to 7% of sales. In the context of the ongoing Organon acquisition, management has established an integration management office and expects the acquisition to finalize in Q4 FY27, with regulatory filings already underway.

Key forward-looking points include:

1. Sales Growth: FY26 saw sales of INR 582 billion, up 11.9% year-over-year, while Q4 FY26 sales reached INR 145,598 million, growing 13.6% compared to Q4 FY25.

2. Gross Margin: The gross margin for Q4 FY26 was at 80.8%, a slight increase from the previous year, attributed to an improved product mix.

3. EBITDA and Net Profit: For Q4 FY26, EBITDA was INR 39,542 million with an EBITDA margin at 27.1%. The net profit after tax for the quarter was reported at INR 27,140 million.

4. Dividend: A final dividend of INR 5 per share has been approved, adding to an interim dividend of INR 11, resulting in a total of INR 16 per share for FY26.

5. U.S. Market Performance: The U.S. sales for FY26 were approximately USD 1.9 billion, reflecting a marginal decline, influenced by lower generic sales amid increased competition.

6. Innovative Medicines: Management highlighted strong growth in innovative medicines, particularly noting that sales for Ilumya reached USD 796 million in FY26, a growth of 16.7%. The acceptance of the BLA for Ilumya for treating adults with active psoriatic arthritis is scheduled for review in October 2026.

7. Market Share: In the Indian pharmaceutical market, Sun Pharma has increased its market share to 8.4%, showing a significant gain since the previous year.

Overall, the management remains optimistic about growth opportunities through strategic R&D investments and the integration of Organon, while navigating challenges in the generic drugs market.

Major Questions and Answers from Sun Pharmaceutical Industries Limited Q4 FY26 Earnings Call

Question 1: Kunal Dhamesha: "If you could share some initial print on UNLOXCYT launch, how has been the doctor's experience with the product? And where is the product making its mark on efficacy, safety side?"

Answer: Richard Ascroft: "The response to UNLOXCYT has been very positive. Physicians appreciate its balance of efficacy and tolerability. We've observed that patients, particularly frail ones, aren't experiencing immune-mediated adverse events, which is unique. We've provided training to healthcare systems to ensure seamless administration. While I can't comment in detail on competitors' strategies regarding the Part B channel, our focus is on securing formulary access and optimizing the physician-patient experience."

Question 2: Kunal Dhamesha: "On the semaglutide launch in India, where do you see our market positioning in this segment over the next year?"

Answer: Kirti Ganorkar: "We launched Noveltreat on March 21 and anticipates it may take 5-6 months to accurately reflect its market position. While we aren't currently in the top three for GLP-1 generics, the product's reception among doctors is promising, especially due to our auto-injector and pen system. We are committed to becoming a market leader over time."

Question 3: Surya Patra: "Could you clarify the sequential drop in margins, especially relating to Revlimid and any one-off costs?"

Answer: Jayashree Satagopan: "The drop due to Revlimid is relatively small, and we did have various non-recurring costs contributing to the overall margin compression. However, we expect normalization in subsequent quarters, as we're managing multiple small components impacting our performance."

Question 4: Surya Patra: "How would the acquisition of Organon complement Sun Pharma's existing business?"

Answer: Kirti Ganorkar: "The Organon acquisition will add women's health and established brands to our existing portfolio, complementing our business without significant product overlap. Biosimilars from Organon will also be a new addition, making it a strategic fit for our innovative medicine segment."

Question 5: Neha: "Rick, is it fair to assume that our specialty growth is largely driven by ILUMYA, and how do you see growth trajectory with new launches in FY27?"

Answer: Richard Ascroft: "For FY26, growth was contributed by not only ILUMYA but also a strong performance across our Innovative Medicines. While ILUMYA will continue to grow, we also project significant contributions from our new launches like LEQSELVI and UNLOXCYT moving forward."

Question 6: Saion Mukherjee: "What was the amount spent last year on new product launches and going forward?"

Answer: Richard Ascroft: "Our spend was around $100 million, and you can expect such initial promotional expenditures will now become part of our base spending to remain competitive across our brands as we expand our patient base."

Question 7: Damayanti Kerai: "Regarding EBITDA margins moving forward, can we expect stabilization given the expenses for UNLOXCYT and LEQSELVI?"

Answer: Jayashree Satagopan: "We do not provide explicit guidance on margins. However, expenses for both UNLOXCYT and LEQSELVI are incorporated into our plans. We anticipate these costs will be ongoing, and margin trajectories will naturally vary."

These summaries encapsulate the questions and their respective answers within the allotted character limit.